Change in Working Time in a Population-Based Cohort of Patients With Breast Cancer
Authors:
- Marie HøyerMHMarie Høyer
- Karin NordinKNKarin Nordin
- Johan AhlgrenJAJohan Ahlgren
- Leif BergkvistLBLeif Bergkvist
- Mats LambeMLMats Lambe
- Birgitta JohanssonBJBirgitta Johansson
- Claudia LampicCLClaudia Lampic
- 10 August 2012
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 30 (23) , 2853-2860
Abstract
Purpose: We examined changes in working time 16 months after a breast cancer diagnosis and identified factors associated with job discontinuation and/or decreased working time. Patients and Methods: This was a population-based cohort study with 735 patients identified in the Regional Breast Cancer Quality Register of Central Sweden. The study sample consisted of 505 women (age < 63 years at diagnosis) who completed questionnaires at baseline and at follow-up (on average 4 and 16 months after diagnosis, respectively). Clinical register data and questionnaire data on sociodemographic factors were obtained at baseline. Self-reported work-related data were obtained at follow-up. Odds ratios were estimated by using logistic regression models. Results: Compared with prediagnosis working time, 72% reported no change in working time, 2% reported an increase, 15% reported a decrease, and 11% did not work at follow-up. Chemotherapy increased the likelihood (odds ratio [OR], 2.45; 95% CI, 1.38 to 4.34) of job discontinuation/decreased working time. Among chemotherapy recipients, associated factors included full-time work prediagnosis (OR, 3.25; 95% CI, 1.51 to 7.01), cancer-related work limitations (OR, 5.26; 95% CI, 2.30 to 12.03), and less value attached to work (OR, 3.69; 95% CI, 1.80 to 7.54). In the nonchemotherapy group, older age (OR, 1.09; 95% CI, 1.02 to 1.17) and less value attached to work (OR, 5.00; 95% CI, 2.01 to 12.45) were associated with the outcome. Conclusion: The majority of women treated for breast cancer returned to their prediagnosis working time. Chemotherapy and cancer-related work limitations are important factors to take into account in identifying women in need of support. Moreover, it is important to consider the woman's own valuation of labor market participation.Keywords
This publication has 28 references indexed in Scilit:
- Breast Cancer, Sickness Absence, Income and Marital Status. A Study on Life Situation 1 Year Prior Diagnosis Compared to 3 and 5 Years after DiagnosisPLOS ONE, 2011
- Cancer survival in Australia, Canada, Denmark, Norway, Sweden, and the UK, 1995–2007 (the International Cancer Benchmarking Partnership): an analysis of population-based cancer registry dataThe Lancet, 2011
- A comparative study of cancer patients with short and long sick-leave after primary treatmentActa Oncologica, 2010
- The impact of sociodemographic, treatment, and work support on missed work after breast cancer diagnosisBreast Cancer Research and Treatment, 2009
- Health-related quality of life in breast cancer patients: A bibliographic review of the literature from 1974 to 2007Journal of Experimental & Clinical Cancer Research, 2008
- Work ability and return-to-work in cancer patientsBritish Journal of Cancer, 2008
- Cost of breast cancer in Sweden in 2002The European Journal of Health Economics, 2007
- Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trialsThe Lancet, 2005
- Cancer, fatigue and the return of patients to work—a prospective cohort studyEuropean Journal of Cancer, 2003
- The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in OncologyJNCI: Journal of the National Cancer Institute, 1993